Dude, wise up. You were told Algernon would have needed to run a 30,000 patient clinical trial. There's no money for that type of trial and the data was not strong enough to do something as stupid as what you suggest they should have done. We are still waiting to complete a 20 Person study in AU/NZ and the last MDA stated they didn't expect final data unytil Q2022. That means it will have taken Algernon at least 2 years to complete a study not even powered for statistical significance. A complete waste of valuable time that cost us further dilution. We are where we are now. Uplisting is the key as we can clearly see too many dumbed down shareholders will keep the company down forever and a day. I don't know about you but I don't have that long in life. I've lowered my expectations of a ROI. Nonetheless, I'd hope management can grow up and finally get it's sh!t together. Stop doling out cheap shares and leave Kal Malhi the F*** alone. Let that clown move on just like Michael Sadhra. If they keep letting that fool flip shares then F management as well. They will never change their wicked ways. The CEO said “The best is yet to come”. There never has been a ‘Best” at Algernon or Breathtec Biomedical. I hope he simply used a poor choice of words/analogy as it relates to reality on his watch as CEO. This is a hopeful waiting period since consolidation. We will find out in short order if the CEO's claim about having our best interest at heart is real or more snake eyes team cobra bs.
peace,
M$
P.S. Look at my last post. in that post there is compelling preclinical data for two molecules yet to get loaded in the pipeline. IF ANYTHING, it's those molecules Algernon should have stuck to the script and gone after versus "the pipe dream" covid angle. We have hella preclinical data just sitting there as the company positions itself for targeting Ifenprodil for anything and everything under the sun. Fine, if that's what Doc Williams truly believes has the best chance of a payday while we're still young. F waiting and waiting and waiting until we're all dead and Kulwant Malhi has flipped every possible share for his personal benefit. Malhi is the only person making money hand over fist trading shares at our expense. Let's get on with the DMT stuff and a couple few Phase 1 clinical trials and hope like hell something catches fire unlike the covid hospital in Romania. WE ONLY NEED ONE HIT FOR ONE DRUG. Meanwhile, run the FN score up/stock up on the DMT front. Just like GH Research. Figure the sh!t out management. UPLIST NASDAQ ASAP
